Immatics (NASDAQ:IMTX) Trading Up 0.1%

Immatics (NASDAQ:IMTX)’s share price rose 0.1% during trading on Thursday . The stock traded as high as $12.81 and last traded at $12.39. Approximately 367,406 shares were traded during mid-day trading, a decline of 26% from the average daily volume of 495,369 shares. The stock had previously closed at $12.38.

Analyst Ratings Changes

Separately, Mizuho raised their target price on Immatics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, May 16th.

Immatics Stock Down 0.7 %

The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -11.60 and a beta of 0.75. The company has a 50-day moving average price of $12.16 and a 200 day moving average price of $11.61.

Immatics (NASDAQ:IMTX) last issued its earnings results on Tuesday, May 14th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.70. The business had revenue of $32.87 million during the quarter, compared to analysts’ expectations of $17.76 million. Immatics had a negative return on equity of 29.36% and a negative net margin of 107.80%. Equities analysts forecast that Immatics will post -1.25 EPS for the current year.

Institutional Trading of Immatics

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its holdings in shares of Immatics by 324.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company’s stock worth $16,310,000 after acquiring an additional 1,183,860 shares in the last quarter. RTW Investments LP raised its holdings in shares of Immatics by 75.7% during the fourth quarter. RTW Investments LP now owns 1,484,911 shares of the company’s stock worth $15,636,000 after acquiring an additional 639,911 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Immatics during the fourth quarter worth $22,113,000. Wasatch Advisors LP purchased a new stake in shares of Immatics during the first quarter worth $7,676,000. Finally, Wellington Management Group LLP raised its holdings in shares of Immatics by 13.3% during the fourth quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company’s stock worth $66,896,000 after acquiring an additional 747,772 shares in the last quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.